Skip to main content
MEDICLIN AG logo

MEDICLIN AG — Investor Relations & Filings

Ticker · MED ISIN · DE0006595101 LEI · 5299007ZHUSGAJRMWH73 F Human health and social work activities
Open in API
Filings indexed 527 across all filing types
Latest filing 2025-02-27 Earnings Release
Country DE Germany
Listing F MED

About MEDICLIN AG

https://www.mediclin.de/

MEDICLIN AG is an operator of healthcare facilities, providing medical services across a network of hospitals, rehabilitation clinics, nursing care homes, and outpatient medical centers. The company's core business is divided into three primary segments: acute care, post-acute care/rehabilitation, and nursing care. It offers specialized inpatient and outpatient treatment in numerous medical fields, including neurology, psychosomatics, orthopedics, internal medicine, cardiology, and oncology. MEDICLIN places a significant emphasis on rehabilitation, engaging in research and developing innovative therapeutic concepts. This includes specialized programs for conditions such as Post-COVID syndrome and a digital teletherapy platform, MEDICLIN HOME, for online rehabilitation.

Recent filings

Filing Released Lang Actions
MEDICLIN presents preliminary figures for the 2024 financial year
Earnings Release Classification · 100% confidence The document is titled "MEDICLIN presents preliminary figures for the 2024 financial year" and provides key financial highlights (sales, operating result) for the full 2024 financial year, comparing them to the previous year. It explicitly states these are 'preliminary figures'. This content structure—a summary of key financial results for a completed period—aligns best with an Earnings Release (ER), which covers initial announcements of periodical financial results (key highlights only). It is not the comprehensive Annual Report (10-K) because it explicitly states the full Annual Report 2024 will be available later (March 28, 2025). It is also not a Call Transcript (CT) or Investor Presentation (IP). Since it is a release of preliminary results, ER is the most appropriate classification. FY 2024
2025-02-27 English
§§ 264 Abs. 3, 264b HGB zum Geschäftsjahr vom 01.01.2024 bis zum 31.12.2024
Audit Report / Information Classification · 95% confidence The document is a formal notification ('Mitteilung') from MediClin Medizinisches Versorgungszentrum GmbH regarding its financial reporting obligations for the fiscal year 2024 (01.01.2024 to 31.12.2024). Specifically, it cites German Commercial Code sections (§§ 264 Abs. 3, 264b HGB) to announce that the company is exempt from the obligation to publicly disclose its annual financial statements ('Befreiung nach § 264 Abs. 3 HGB'). Instead, the information will be disclosed within the consolidated financial statements of the parent company (MEDICLIN AKTIENGESELLSCHAFT). This document is not the full Annual Report (10-K) or a standard Audit Report (AR), but rather a specific regulatory disclosure concerning the publication status of those reports. Since it deals with the formal status and disclosure requirements of annual financial information, and it is a specific regulatory notice, it fits best under the general 'Regulatory Filings' category (RNS) as it is a mandatory notification about compliance status, rather than a core financial statement or management discussion. FY 2024
2025-02-10 German
§§ 264 Abs. 3, 264b HGB zum Geschäftsjahr vom 01.01.2024 bis zum 31.12.2024
Audit Report / Information Classification · 95% confidence The document is titled 'Finanzbericht' (Financial Report) and explicitly references German commercial code sections (§§ 264 Abs. 3, 264b HGB) concerning exemptions from preparing and disclosing annexes, management reports, and annual financial statements for the fiscal year 2024. It details a shareholder resolution ('Gesellschafterbeschluss') granting this exemption based on inclusion in the consolidated financial statements of the parent company (MEDICLIN Aktiengesellschaft). This type of document, dealing with specific accounting treatments, exemptions, and shareholder resolutions related to annual reporting requirements under German law, aligns best with the 'Audit Report / Information' category (AR), as it concerns the application of accounting principles and reporting obligations, even though it is a resolution granting an exemption rather than a full audit report. It is not a full 10-K, nor is it a general earnings release (ER) or a presentation (IP). Given the focus on statutory financial reporting compliance and exemptions, AR is the most appropriate fit among the provided options. FY 2024
2025-02-05 German
MEDICLIN raises full-year guidance for the 2024 financial year
Earnings Release Classification · 100% confidence The document is a short announcement dated January 21, 2025, titled "MEDICLIN raises full-year guidance for the 2024 financial year." It explicitly states that the company is raising its guidance for EBIT and sales forecasts. It also mentions that the preliminary figures for the full year will be published later (February 27, 2025). This is a pre-release announcement of updated financial expectations, not the full earnings release (ER) or the comprehensive interim/annual report (IR/10-K). Since it is an announcement updating financial outlook/forecasts, it most closely aligns with an Earnings Release (ER) which covers periodical financial results highlights, even though this specific one is a guidance raise rather than the final result release itself. Given the options, ER is the best fit for a short, high-level financial update preceding the full results publication. FY 2024
2025-01-22 English
MEDICLIN raises full-year guidance for the 2024 financial year
Earnings Release Classification · 100% confidence The document is a short announcement dated January 21, 2025, titled 'MEDICLIN raises full-year guidance for the 2024 financial year'. It explicitly states it is an 'Ad-hoc' disclosure of 'inside information acc. to Article 17 MAR'. It provides updated guidance figures (EBIT and Sales forecast) for the 2024 financial year and mentions that the preliminary figures will be published later (February 27, 2025). This is a forward-looking statement updating financial expectations, which is typically classified as an Earnings Release (ER) if it contains key highlights, or sometimes falls under Regulatory Filings (RNS) if it's a mandatory MAR disclosure that doesn't fit other categories. Since it is a direct announcement of revised financial outlook/forecast, it aligns best with the 'Earnings Release' (ER) category, which covers initial announcements of periodical financial results and key highlights, even if it's a guidance update rather than the final result itself. Given the short length and the nature of updating guidance, it is not a full report (10-K, IR). It is a specific financial update, making ER the most appropriate fit over the general RNS. FY 2024
2025-01-21 English
MEDICLIN hebt Jahresprognose fur das Geschaftsjahr 2024 an
Regulatory Filings Classification · 99% confidence The document is a short announcement dated January 21, 2025, titled "MEDICLIN hebt Jahresprognose für das Geschäftsjahr 2024 an" (MEDICLIN raises annual forecast for fiscal year 2024). It explicitly states that it is an 'Insiderinformation nach Artikel 17 der Verordnung (EU) Nr. 596/2014' (Inside Information according to Article 17 of Regulation (EU) No 596/2014). This type of announcement, which updates financial expectations (EBIT and Revenue forecasts) outside of scheduled reporting dates, is typically classified as a general regulatory announcement or an earnings/guidance update. Since it is not the full Earnings Release (ER) or Interim Report (IR), but rather a specific guidance revision, it fits best under the general Regulatory Filings (RNS) category, as it is a mandatory disclosure under EU market abuse rules, or potentially a Capital/Financing Update (CAP) if the change was related to capital structure, but here it is purely operational/financial guidance. Given the context of mandatory disclosure via EQS News (often used for RNS), RNS is the most appropriate general regulatory fallback. It is too short and specific to be an ER or MDA. It is not a formal report itself, so RPA is less likely than RNS for this type of mandatory market information.
2025-01-21 German

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.